Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Longitudinal MRI in Multiple Sclerosis:Correlation Between Disability and Lesion Burden
Neurol 44:2120-2124, Khoury,S.J.,et al, 1994
Clinical Worsening in MS is Associated with Incr'd Freq & Area of Gadopenetate Dimeglumine-enhancing MRI Lesions
Ann Neurol 33:480-489, Smith,M.E.,et al, 1993
A Correlative Triad of Gadolinium-DTPA MRI, EDSS, & CSF-MBP in Relapsing MS Treated with High-Dose Intravenous Methylprednisolone
Neurol 42:63-67, Barkhof,F.,et al, 1992
Cognitive Loss in Multiple Sclerosis
Arch Neurol 46:162-167, Franklin,G.M.,et al, 1989
The Influence of Pregnancy on Disability From Multiple Sclerosis:A Population in Middlesex County, Ontario
Neurol 39:1438-1440, Weinshenker,B.G.,et al, 1989